Compare MLSS & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLSS | ALLR |
|---|---|---|
| Founded | 1989 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 25.6M |
| IPO Year | 1996 | 2021 |
| Metric | MLSS | ALLR |
|---|---|---|
| Price | $0.35 | $1.43 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.00 | ★ $9.75 |
| AVG Volume (30 Days) | ★ 221.9K | 219.2K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,973,982.00 | $320,000.00 |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $8.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.99 | N/A |
| 52 Week Low | $0.22 | $0.77 |
| 52 Week High | $0.92 | $2.35 |
| Indicator | MLSS | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 44.62 | 44.65 |
| Support Level | $0.24 | $1.34 |
| Resistance Level | $0.40 | $1.80 |
| Average True Range (ATR) | 0.03 | 0.14 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 1.83 | 2.50 |
Milestone Scientific Inc develops and commercializes proprietary computer-controlled drug delivery systems designed to enhance the safety, precision, and patient experience associated with subcutaneous injections and fluid aspiration procedures. The company's core technology platform, Dynamic Pressure Sensing (DPS) Technology, controls flow rate and measures pressure at the needle tip in real time. DPS Technology is incorporated into both the company's dental and medical products and supports clinical applications, including local anesthesia delivery, epidural space identification in regional anesthesia procedures, and intra-articular joint injections. It operates in two segments: Dental, which markets and sells its dental products, and Medical, markets and sells its medical products.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States. It is focused on the clinical development of its lead program: Stenoparib, which is being co-developed with a drug specific DRP companion diagnostic.